# Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

> **NCT05485350** · PHASE2 · UNKNOWN · sponsor: **Peking University Third Hospital** · enrollment: 32 (estimated)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Anlotinib Hydrochloride
- **DRUG:** penpulimab
- **RADIATION:** SBRT

## Key facts

- **NCT ID:** NCT05485350
- **Lead sponsor:** Peking University Third Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-09-12
- **Primary completion:** 2023-09-21
- **Final completion:** 2024-10-15
- **Target enrollment:** 32 (ESTIMATED)
- **Last updated:** 2022-08-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05485350

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05485350, "Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05485350. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*